Prevalence and clinical significance of igg isotype anti-β2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study with anticardiolipin antibodies

Journal of Laboratory and Clinical Medicine

Volumn 129, Issue 5, 1997, Pages 499-506

  Sanmarco, Marielle ^a   Soler, Christophe ^b   Christides, Christine ^b   Raoult, Didier ^b   Weiller, Pierre Jean ^b   Gerolami, Victoria ^b   Bernard, Dominique ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031147942     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(97)90004-4     Document Type: Article

References (40)

1. Harris EN, Chan JK, Asherson RA, Aber V, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin test. Arch Intern Med 1986;146:2153-6.
2. Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1989;20:52-67.
3. Love PE, Santoro SA. Antiphospholipid syndrome: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990;112:682-9.
4. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991;49:193-280.
5. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997-1002.
6. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486-9.
7. Vianna JL, Haga HJ, Tripathi P, Cervera R, Khamashta MA, Hughes GAV. Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis 1992;51:160-1.
8. Asherson RA. The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis 1992;51:147-50.
9. Piette JC, Wechsler B, Bletry O, et al. Antiphospholipid syndrome. The clinician's point of view. Ann Med Interne (Paris) 1992;143:392-5.
10. Alarcon-Segovia D. Antiphospholipid syndrome within systemic lupus erythematosus. Lupus 1994;3:289-91.
11. Alarcon-Segovia D. Clinical manifestations of the Antiphospholipid Syndrome. J Rheumatol 1992;19:1778-81.
12. Harris EN. The Antiphospholipid Syndrome. Diagnosis, management, and pathogenesis. Clin Rev Allergy Immunol 1995;13:39-48.
13. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid antibody syndrome: major clinical and serological features. Medicine (Baltimore) 1989;68:366-74.
14. Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-8.
15. Asherson RA, Cervera R. "Primary," "Secondary" and other variants of the antiphospholipid syndrome. Lupus 1994;3: 293-8.
16. McNeil PH, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2 Glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
17. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune diseases. Lancet 1990;335:177-8.
18. Chamley LW, McKay EJ, Pattison NS. Cofactor dependent and cofactor independent anticardiolipin antibodies. Thromb Res 1991;61:291-9.
19. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to plasma protein cofactor. Lancet 1990;335:1544-7.
20. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using β2-Glycoprotein I as an antigen. J Immunol Methods 1991; 143:223-9.
21. Keeling DM, Wilson AJG, Mackie IJ, Machin SJ, Isenberg DA. Some "antiphospholipid" antibodies bind to β2 Glycoprotein 1 in the absence of phospholipid. Br J Haematol 1992;82:571-4.
22. Viard JP, Amoura Z, Bach JF. Association of anti-β2 Glycoprotein I antibodies with lupus type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-6.
23. 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:122-30.
24. Matsuda J, Saitoh N, Gohchi K, Tsukamoto M. Prevalence of β2-glycoprotein I antibody in systemic lupus erythematosus with β2-glycoprotein I dependent antiphospholipid antibodies. Ann Rheum Dis 1995;54:73-5.
25. Nomura M, Okada J, Kondo H. Detection of bovine β2-glycoprotein I in sera from patients with antiphospholipid syndrome. Rheumatol Int 1995;15:1-8.
26. Martinuzzo ME, Forastiero RR, Carreras LO. Anti-β2-glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995;89:397-402.
27. Pierangeli SS, Harris EN, Davis SA, De Lorenzo G. β2 Glycoprotein 1 (β2 GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992;82:565-70.
28. Gharavi AE, Harris EN, Sammaritano R, Pierangeli SS, Wen J. Do patients with antiphospholipid syndrome have autoantibodies to β2-glycoprotein I? J Lab Clin Med 1993;122:426-31.
29. Roubey RAS, Winfield JB. Certain lupus anticoagulant recognize neo-antigens of phospholipid-bound β2 Glycoprotein 1. Thromb Haemost 1993;69:1011. Abstract.
30. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-Glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-62.
31. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize β2-Glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954-60.
32. Tan EM, Cohen AS, Fries JF, et al. Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
33. Galen RS, Gambino RS. Beyond normality: the predictive value and efficiency of medical diagnoses. New York: John Wiley and sons, 1975.
34. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995;73:29-34.
35. Triolo PM, Andrade DJ. Surface modification and evaluation of some commonly used catheter materials. I. Surface properties. J Biomed Mater Res 1983;17:129-47.
36. Sanmarco M, Soler C. Heterogeneity of anti-β2-glycoprotein I antibodies. Nouv Rev Fr Hematol 1995;37(suppl II):57-60.
37. Cabrai AR, Cabiedes J, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in SLE associate more strongly with anti-β2-glycoprotein-1 than with antiphospholipid antibodies [abstract]. Lupus 1995; 4(suppl):149.
38. Ordi J, Falga C, Monegal F, et al. Anti-β2 Glycoprotein 1 antibodies in patients with aPL related diseases. Lupus 1994; 3:334. Abstract.
39. Guerin J, Feighery C, Sim RB, Jackson J. Detection of antibodies to β2 Glyco-protein I using an ELISA. Lupus 1994;3:327. Abstract.
40. Loizou S, Cabazon JK, Athanassiou P, Walport MJ. Relationship between anti-β2 glycoprotein I and anticardiolipin antibodies. Lupus 1994;3:364. Abstract.